Today
July 25, 2026Dilution Risk
3Last 7DListing Risk
37Last 30DEarnings
9Last 7DInsider / Ownership
3Last 14DDividends
1Last 30DFDA / Clinical
13Last 30DQ1 results released; company completed US$750M Senior Secured Notes offering.
Filed a $300M shelf and $100M ADS ATM, creating large potential sell pressure.
Automatic shelf registers ordinary, preferred shares and warrants; terms set in supplements.
Universal shelf filed; registered-share count conflicts need verification.
Resale registration for 13.02M shares creates urgent dilution and overhang risk.
Director Roelof Botha received 13,201 restricted stock units on 2026-05-13.
Nasdaq requires AVX to regain $1 bid price compliance by July 6, 2026; reverse split may be proposed May 29, 2026.
Company entered an ATM agreement to sell ordinary shares, raising up to $17M.
Indenture allows issuance of up to 34.85M dilutive warrants.
Announced up-to-$100M ATM sales agreement, enabling potential dilution.
Company faces NYSE American noncompliance and issued large exercisable pre-funded warrants.
Shareholders vote June 22, 2026 on Psyga acquisition, significant ADS issuance, share-cap increase, and financing.
Q1 results: Phase 3 prep progressing, but cash runway is critically low.